Report cover image

Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 199 Pages
SKU # APRC20556271

Description

Summary

According to APO Research, the global Drugs for Vancomycin-Resistant Enterococcus Faecium market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Drugs for Vancomycin-Resistant Enterococcus Faecium market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Drugs for Vancomycin-Resistant Enterococcus Faecium market include Microbiotix, MGB Biopharma Limited, Lytix Biopharma, LegoChem Biosciences, Helix BioMedix, Enanta Pharmaceuticals, Cellceutix Corporation, Aphios Corporation and Alvogen, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Drugs for Vancomycin-Resistant Enterococcus Faecium, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Drugs for Vancomycin-Resistant Enterococcus Faecium, also provides the value of main regions and countries. Of the upcoming market potential for Drugs for Vancomycin-Resistant Enterococcus Faecium, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Vancomycin-Resistant Enterococcus Faecium revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Drugs for Vancomycin-Resistant Enterococcus Faecium market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Drugs for Vancomycin-Resistant Enterococcus Faecium company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Company

Microbiotix
MGB Biopharma Limited
Lytix Biopharma
LegoChem Biosciences
Helix BioMedix
Enanta Pharmaceuticals
Cellceutix Corporation
Aphios Corporation
Alvogen
Alchemia Limited
Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Type

Ampicillin
Daptomycin
Quinupristin/dalfopristin
Linezolid
Chloramphenicol
Others
Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Application

Hospital
Clinic
Others
Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Drugs for Vancomycin-Resistant Enterococcus Faecium status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Drugs for Vancomycin-Resistant Enterococcus Faecium key companies, revenue, market share, and recent developments.
3. To split the Drugs for Vancomycin-Resistant Enterococcus Faecium breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Drugs for Vancomycin-Resistant Enterococcus Faecium market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drugs for Vancomycin-Resistant Enterococcus Faecium significant trends, drivers, influence factors in global and regions.
6. To analyze Drugs for Vancomycin-Resistant Enterococcus Faecium competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vancomycin-Resistant Enterococcus Faecium market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vancomycin-Resistant Enterococcus Faecium and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vancomycin-Resistant Enterococcus Faecium.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Vancomycin-Resistant Enterococcus Faecium industry.
Chapter 3: Detailed analysis of Drugs for Vancomycin-Resistant Enterococcus Faecium company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Drugs for Vancomycin-Resistant Enterococcus Faecium in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Drugs for Vancomycin-Resistant Enterococcus Faecium in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size, 2020 VS 2024 VS 2031
1.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Drugs for Vancomycin-Resistant Enterococcus Faecium Market Dynamics
2.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Trends
2.2 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Drivers
2.3 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Opportunities and Challenges
2.4 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Restraints
3 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Company
3.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Revenue Ranking in 2024
3.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Company (2020-2025)
3.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Ranking (2023-2025)
3.4 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Manufacturing Base and Headquarters
3.5 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Product Type and Application
3.6 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Drugs for Vancomycin-Resistant Enterococcus Faecium Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Type
4.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Type Introduction
4.1.1 Ampicillin
4.1.2 Daptomycin
4.1.3 Quinupristin/dalfopristin
4.1.4 Linezolid
4.1.5 Chloramphenicol
4.1.6 Others
4.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type
4.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2020-2031)
4.2.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type (2020-2031)
5 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Application
5.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application
5.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2020-2031)
5.2.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application (2020-2031)
6 Drugs for Vancomycin-Resistant Enterococcus Faecium Regional Value Analysis
6.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2020-2031)
6.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region: 2020-2025
6.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2020-2031)
6.3.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2020-2031)
6.4.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2020-2031)
6.5.2 Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2020-2031)
6.6.2 South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2020-2031)
6.7.2 Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2024 VS 2031
7 Drugs for Vancomycin-Resistant Enterococcus Faecium Country-level Value Analysis
7.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2020-2031)
7.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2020-2025)
7.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.3.2 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.4.2 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.6.2 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.7.2 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.7.3 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.9.2 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.10.2 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.11.2 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.14.2 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.14.3 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.15.2 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.17.2 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.17.3 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.18.2 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.22.2 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.24.2 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.26.2 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.27.2 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.29.2 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Microbiotix
8.1.1 Microbiotix Comapny Information
8.1.2 Microbiotix Business Overview
8.1.3 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.1.4 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.1.5 Microbiotix Recent Developments
8.2 MGB Biopharma Limited
8.2.1 MGB Biopharma Limited Comapny Information
8.2.2 MGB Biopharma Limited Business Overview
8.2.3 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.2.4 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.2.5 MGB Biopharma Limited Recent Developments
8.3 Lytix Biopharma
8.3.1 Lytix Biopharma Comapny Information
8.3.2 Lytix Biopharma Business Overview
8.3.3 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.3.4 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.3.5 Lytix Biopharma Recent Developments
8.4 LegoChem Biosciences
8.4.1 LegoChem Biosciences Comapny Information
8.4.2 LegoChem Biosciences Business Overview
8.4.3 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.4.4 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.4.5 LegoChem Biosciences Recent Developments
8.5 Helix BioMedix
8.5.1 Helix BioMedix Comapny Information
8.5.2 Helix BioMedix Business Overview
8.5.3 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.5.4 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.5.5 Helix BioMedix Recent Developments
8.6 Enanta Pharmaceuticals
8.6.1 Enanta Pharmaceuticals Comapny Information
8.6.2 Enanta Pharmaceuticals Business Overview
8.6.3 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.6.4 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.6.5 Enanta Pharmaceuticals Recent Developments
8.7 Cellceutix Corporation
8.7.1 Cellceutix Corporation Comapny Information
8.7.2 Cellceutix Corporation Business Overview
8.7.3 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.7.4 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.7.5 Cellceutix Corporation Recent Developments
8.8 Aphios Corporation
8.8.1 Aphios Corporation Comapny Information
8.8.2 Aphios Corporation Business Overview
8.8.3 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.8.4 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.8.5 Aphios Corporation Recent Developments
8.9 Alvogen
8.9.1 Alvogen Comapny Information
8.9.2 Alvogen Business Overview
8.9.3 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.9.4 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.9.5 Alvogen Recent Developments
8.10 Alchemia Limited
8.10.1 Alchemia Limited Comapny Information
8.10.2 Alchemia Limited Business Overview
8.10.3 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2020-2025)
8.10.4 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
8.10.5 Alchemia Limited Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.